No products in the cart.
Pre-made Flotetuzumab benchmark antibody ( Bispecific scFv with Crossover, anti-IL3RA;CD3E therapeutic antibody, Anti-CD123/IL3RX/IL3RY/IL3RAY/hIL-3Ra;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-218
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Flotetuzumab biosimilar, Bispecific scFv with Crossover, Anti-IL3RA;CD3E Antibody: Anti-CD123/IL3RX/IL3RY/IL3RAY/hIL-3Ra;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Flotetuzumab (INN; development code MGD006) is a bispecific antibody designed for the treatment of acute myeloid leukemia.
| Products Name (INN Index) | Pre-Made Flotetuzumab biosimilar, Bispecific scFv with Crossover, Anti-IL3RA;CD3E Antibody: Anti-CD123/IL3RX/IL3RY/IL3RAY/hIL-3Ra;T3E/TCRE/IMD18 therapeutic antibody |
|---|---|
| INN Name | Flotetuzumab |
| Target | IL3RA,CD3E |
| Format | Bispecific scFv with Crossover |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | NA |
| VD LC | Kappa,Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | MacroGenics,Servier |
| Conditions Approved | NA |
| Conditions Active | Acute myeloid leukaemia,Myelodysplastic syndromes,Precursor cell lymphoblastic leukaemia-lymphoma |
| Conditions Discontinued | NA |
| Development Tech | Dual-Affinity?Re-targenting (DART?) |
| Previous Name | NA |
| Gm Offical Target Name | IL3RA,CD3E |
| Package |
Previous slide
Next slide
